精密医療の共同研究・ライセンシング契約（2019年～2025年）

当レポートでは、世界のバイオ医薬品産業について調査分析し、2019年～2025年の精密医療の共同研究・ライセンシング契約1,221件に関する、契約条件などの詳細なデータを提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 精密医療契約の動向

• イントロダクション
• 過去数年の精密医療契約
• もっとも活発な精密医療交渉者
• 精密医療契約：契約タイプ別
• 精密医療契約：治療領域別
• 精密医療契約：産業部門別
• 精密医療契約の契約条件
  • 精密医療契約のヘッドライン金額
  • 精密医療契約の前払い
  • 精密医療契約のマイルストーン払い
  • 精密医療のロイヤルティ率

第3章 主な精密医療契約

• イントロダクション
• 上位の精密医療契約（金額）

第4章 もっとも活発な精密医療交渉者

• イントロダクション
• もっとも活発な精密医療交渉者
• もっとも活発な精密医療契約企業のプロファイル

第5章 精密医療契約ディレクトリ

• イントロダクション
• 精密医療契約ディレクトリ

第6章 精密医療の契約：技術タイプ別

• 契約ディレクトリ
• 契約ディレクトリ - 精密医療契約：企業別（A-Z）
• 契約ディレクトリ - 精密医療契約：契約タイプ別
• 契約ディレクトリ - 精密医療契約：治療領域別
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

Precision Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1221 precision medicine deals announced since 2019 including financial terms where available including links to online deal records of actual precision medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine dealmaking since 2019.

Chapter 3 provides an overview of the leading precision medicine deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine dealmaking with a brief summary followed by a comprehensive listing of precision medicine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine partnering deals signed and announced since Jan 2019. The chapter is organized by specific precision medicine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse precision medicine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Precision Medicine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine Collaboration and Licensing Deals includes:

• Trends in precision medicine dealmaking in the biopharma industry
• Directory of precision medicine deal records covering pharmaceutical and biotechnology
• The leading precision medicine deals by value
• Most active precision medicine licensing dealmakers
• Precision Medicine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine dealmaking

• 2.1. Introduction
• 2.2. Precision medicine deals over the years
• 2.3. Most active precision medicine dealmakers
• 2.4. Precision medicine deals by deal type
• 2.5. Precision medicine deals by therapy area
• 2.6. Precision medicine deals by industry sector
• 2.7. Deal terms for precision medicine deals
  • 2.7.1 Precision medicine deals headline values
  • 2.7.2 Precision medicine deal upfront payments
  • 2.7.3 Precision medicine deal milestone payments
  • 2.7.4 Precision medicine royalty rates

Chapter 3 - Leading precision medicine deals

• 3.1. Introduction
• 3.2. Top precision medicine deals by value

Chapter 4 - Most active precision medicine dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine dealmakers
• 4.3. Most active precision medicine deals company profiles

Chapter 5 - Precision medicine contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine contracts dealmaking directory

Chapter 6 - Precision medicine dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine deals by company A-Z
• Deal directory - Precision medicine deals by deal type
• Deal directory - Precision medicine deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine deals since 2019
• Figure 2: Active precision medicine dealmaking activity - 2019 - 2025
• Figure 3: Precision medicine deals by deal type since 2019
• Figure 4: Precision medicine deals by therapy area since 2019
• Figure 5: Precision medicine deals by industry sector since 2019
• Figure 6: Precision medicine deals with a headline value
• Figure 7: Precision medicine deals with an upfront value
• Figure 8: Precision medicine deals with a milestone value
• Figure 9: Precision medicine deals with a royalty rate value
• Figure 10: Top precision medicine deals by value since 2019
• Figure 11: Most active precision medicine dealmakers 2019 - 2025
• Figure 12: Precision medicine deals by technology type since 2019